搜尋
Telix Pharmaceuticals Ltd
TLX添加自選
9.910USD
-0.150-1.49%
收盤 07-31 16:00（美東）報價延遲15分鐘
0.00總市值
--本益比TTM
關於 Telix Pharmaceuticals Ltd 公司
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Telix Pharmaceuticals Ltd簡介
公司代碼TLX
公司名稱Telix Pharmaceuticals Ltd
上市日期Nov 15, 2017
CEOOrtiz (Raphaeel)
員工數量- -
證券類型Depository Receipt
年結日- -
公司地址55 Flemington Road
城市MELBOURNE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Australia
郵編3051
電話61390933855
網址https://telixpharma.com/
公司代碼TLX
上市日期Nov 15, 2017
CEOOrtiz (Raphaeel)
Telix Pharmaceuticals Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Darren Smith, CPA
Mr. Darren Smith, CPA
Group Chief Financial Officer
Group Chief Financial Officer
--
--
Mr. Kevin Richardson
Mr. Kevin Richardson
Chief Executive Officer - Telix Precision Medicine
Chief Executive Officer - Telix Precision Medicine
--
--
Mr. Raphaeel Ortiz
Mr. Raphaeel Ortiz
Chief Executive Officer - Telix International
Chief Executive Officer - Telix International
--
--
Ms. Genevieve Ryan
Ms. Genevieve Ryan
Company Secretary
Company Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Dr. Christian P. Behrenbruch, J.D., Ph.D.
Group Chief Executive Officer, Managing Director, Executive Director
Group Chief Executive Officer, Managing Director, Executive Director
--
--
Dr. Mark Nelson, Ph.D.
Dr. Mark Nelson, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jann Skinner
Ms. Jann Skinner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. David Cade
Dr. David Cade
Group Chief Medical Officer
Group Chief Medical Officer
--
--
Mr. Richard Valeix
Mr. Richard Valeix
Group Chief Commercial Officer
Group Chief Commercial Officer
--
--
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
常見問題
Telix Pharmaceuticals Ltd的前五大股東是誰？
Telix Pharmaceuticals Ltd的前五大股東如下：Dr. Christian P. Behrenbruch, J.D., Ph.D.
有多少機構持有Telix Pharmaceuticals Ltd(TLX)的股份？
截至2026Q1，共有61家機構持有Telix Pharmaceuticals Ltd的股份，合計持有的股份價值約為1.47M，占公司總股份的0.43% 。與2025Q4相比，機構持股有所增加，增幅為326197.00。